Study Claims Popular Anti-cholesterol Drug Crestor Cuts Heart Disease Risk by 44 Percent

by Tanya Thomas on  November 10, 2008 at 5:36 PM Heart Disease News
RSS Email Print This Page Comment bookmark
Font : A-A+

A new study has claimed that the world's most popular anti-cholesterol drug Crestor, could be of use in more ways than one. Among patients who currently don't face a high risk of getting a heart disease, Crestor could reduce their risk further by nearly 44 percent.
Study Claims Popular Anti-cholesterol Drug Crestor Cuts Heart Disease Risk by 44 Percent
Study Claims Popular Anti-cholesterol Drug Crestor Cuts Heart Disease Risk by 44 Percent

The results of the study named JUPITER were presented at an annual meeting of the American Heart Association in New Orleans and were published online by the New England Journal of Medicine.

Show Full Article

The study of 17,802 men and women aged 50 and more demonstrated that 20 milligrams of Crestor taken daily significantly reduced the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes by 44 percent compared to placebo among men and women with elevated hsCRP but low to normal cholesterol levels.

CRP is a protein produced by the liver that plays an important role in inflammatory processes and serves as a biological marker to measure the risk of artery blockage.

The research also showed that for patients in the trial taking Crestor the combined risk of heart attack, stroke or death from heart disease was reduced by 47 percent, the risk of heart attack was cut by more than half, the risk of stroke by nearly half and total mortality was reduced by 20 percent.

"These results provide new information about Crestor's effects on CV risk," said Howard Hutchinson, chief medical officer for pharmaceutical company AstraZeneca, which markets Crestor.

"The JUPITER trial confirmed that Crestor dramatically reduces LDL-C cholesterol levels and has now demonstrated a nearly 50 percent reduction in the risk of heart attack and stroke in a population of patients who had elevated hsCRP but low to normal cholesterol levels," Hutchinson added. "As is appropriate, the medical community, regulators, and guideline committees will now carefully consider these data and any implications for treating patients."

The study showed that a daily dose of 20 milligrams of Crestor was well tolerated in nearly 9,000 patients during the course of the trial.

There was no difference between treatment groups for major adverse events, including cancer or myopathy, the report said.

But there was a small increase in physician reported diabetes consistent with data from other large placebo controlled statin trials.

Crestor has now received regulatory approval in over 95 countries. Nearly 15 million patients have been prescribed Crestor worldwide.

Source: AFP

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Since my cardiologist gave me a CT scan of the heart which showed I had 45 to 50% blockages in most of the arteries, my primary physician said I should try Crestor. I don't smoke, have maybe 25 extra pounds, but because of a family history of heart desease (parents dead by the time I was 22)I'm clogged up like a can of crisco. But since women are underdiagnosed on heart desease and I'm only 52, I figure I'll be proactive and give this stuff a try. I'll let you know.

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive